Loading institutional data...
Loading institutional data...
Held by 2,218 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $150.89 today, the market must believe free cash flow compounds 9.9%/yr for a decade (off $9.1B normalized FCF).
The market's 9.9% is more optimistic than its 9-yr track record.
2-stage DCF · 1.24B shares · net debt $24.9B
mean -2.5% · volatility σ 28% · implied rate exceeded in 3/9 yrs
Central path = implied 9.9%/yr growth; shaded band = ±1σ (28%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 42% of free cash flow, leaving room to grow it and fund buybacks. Last year: $4.0B dividends + $1.9B buybacks = $5.9B returned on $9.5B FCF.
9 consecutive years of dividend increases · 6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 18%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
$2.8B of principal comes due within a year. Scheduled principal only (excludes interest & revolver draws). As of 2020-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~4.1% on $24.9B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.44B 100.0% | $28.75B 100.0% | $27.12B 100.0% | $27.28B 100.0% | $27.30B 100.0% | $24.69B 100.0% | $22.45B 100.0% | $22.13B 100.0% | $26.11B 100.0% | $30.39B 100.0% |
| Cost of Revenue | $6.23B 21.2% | $6.25B 21.7% | $6.50B 24.0% | $5.66B 20.7% | $6.60B 24.2% | $4.57B 18.5% | $4.67B 20.8% | $4.85B 21.9% | $4.37B 16.7% | $4.26B 14.0% |
| Cost of Products | — | — | — | — | — | — | — | — | $4.37B 16.7% | $4.26B 14.0% |
| Research & Development | — | — | — | — | — | — | $9.11B 40.6% | $5.02B 22.7% | $3.73B 14.3% | $5.10B 16.8% |
| Selling, General & Admin | $5.77B 19.6% | $6.09B 21.2% | $6.09B 22.5% | $5.67B 20.8% | $5.25B 19.2% | $5.15B 20.9% | $4.38B 19.5% | $4.06B 18.3% | $3.88B 14.9% | $3.40B 11.2% |
| Total Operating Expenses | $19.42B 66.0% | $27.09B 94.2% | $19.51B 72.0% | $19.95B 73.1% | $17.39B 63.7% | $20.62B 83.5% | $18.16B 80.9% | $13.93B 62.9% | $11.98B 45.9% | $12.76B 42.0% |
| Operating Income | $10.02B 34.0% | $1.66B 5.8% | $7.61B 28.0% | $7.33B 26.9% | $9.92B 36.3% | $4.07B 16.5% | $4.29B 19.1% | $8.20B 37.1% | $14.12B 54.1% | $17.63B 58.0% |
| Interest Expense | $1.02B 3.5% | $977.0M 3.4% | $944.0M 3.5% | $935.0M 3.4% | $1.00B 3.7% | $984.0M 4.0% | $995.0M 4.4% | $1.08B 4.9% | $1.12B 4.3% | $964.0M 3.2% |
| Other Income (Expense), net | $798.0M 2.7% | $6.0M 0.0% | $198.0M 0.7% | -$581.0M -2.1% | -$639.0M -2.3% | -$1.42B -5.7% | $1.87B 8.3% | $676.0M 3.1% | $523.0M 2.0% | $428.0M 1.4% |
| Pretax Income | $9.80B 33.3% | $690.0M 2.4% | $6.86B 25.3% | $5.81B 21.3% | $8.28B 30.3% | $1.67B 6.8% | $5.16B 23.0% | $7.80B 35.2% | $13.53B 51.8% | $17.10B 56.3% |
| Income Tax Expense | $1.29B 4.4% | $211.0M 0.7% | $1.25B 4.6% | $1.25B 4.6% | $2.08B 7.6% | $1.58B 6.4% | -$204.0M -0.9% | $2.34B 10.6% | $8.88B 34.0% | $3.61B 11.9% |
| Net Income | $8.51B 28.9% | $480.0M 1.7% | $5.67B 20.9% | $4.59B 16.8% | $6.22B 22.8% | $123.0M 0.5% | $5.39B 24.0% | $5.46B 24.7% | $4.63B 17.7% | $13.50B 44.4% |
| Per Share | ||||||||||
| EPS (Basic) | $6.84 | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 | $3.54 | $10.08 |
| EPS (Diluted) | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 |
| Weighted Avg Shares (Basic) | 1.24B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B |
| Weighted Avg Shares (Diluted) | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 91th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 209.9× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 21.9 | 20.8 | 18.5 | 24.2 | 20.7 | 24.0 | 21.7 | 21.2 |
| R&D | 22.7 | 40.6 | — | — | — | — | — | — |
| SG&A | 18.3 | 19.5 | 20.9 | 19.2 | 20.8 | 22.5 | 21.2 | 19.6 |
| Operating Income | 37.1 | 19.1 | 16.5 | 36.3 | 26.9 | 28.0 | 5.8 | 34.0 |
| Income Tax | 10.6 | -0.9 | 6.4 | 7.6 | 4.6 | 4.6 | 0.7 | 4.4 |
| Net Income | 24.7 | 24.0 | 0.5 | 22.8 | 16.8 | 20.9 | 1.7 | 28.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GILD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
Peers = companies sharing GILD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.